Caris Molecular Intelligence
Overview
Caris Molecular Intelligence is a comprehensive tumor profiling service that leverages artificial intelligence (AI) to identify key molecular features of cancer. It provides oncologists with critical clinical insights to guide personalized therapies and facilitate clinical trial matching. The service reveals a molecular blueprint across DNA, RNA, and proteins, enabling individualized treatment decisions for patients.
Caris supports the full continuum of cancer care, from disease detection and therapy selection (through both tissue-based and blood-based profiling) to treatment monitoring. Its offerings include advanced assays like Caris Assure (blood-based, utilizing circulating Nucleic Acid Sequencing – cNAS) and MI Profile (tissue-based comprehensive testing). The platform also features AI Signatures such as Caris GPSai and Caris FOLFIRSTai, and supports multidisciplinary care through the Caris Molecular Tumor Board and Right-In-Time Trials.
For biopharma partners, Caris Molecular Intelligence informs and empowers precision oncology programs, accelerating drug discovery, translational medicine, clinical development, and commercialization by combining massive amounts of genomic, transcriptomic, and proteomic data with clinical outcomes in one of the world’s largest multimodal databases.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Comprehensive Tumor Profiling (DNA, RNA, Proteins)
- AI-Powered Clinical Insights
- Personalized Therapy Recommendations
- Clinical Trial Matching (Right-In-Time Trials)
- Disease Detection & Treatment Monitoring
- Tissue-Based Profiling (MI Profile, MI Cancer Seek Hybrid)
- Blood-Based Profiling (Caris Assure)
- AI Signatures (Caris GPSai, Caris FOLFIRSTai)
- Caris Molecular Tumor Board
- EHR Integrations (e.g., Epic ORA, OncoEMR)
Use Cases
- Guiding individualized treatment decisions for oncologists
- Informing personalized treatment options for cancer patients
- Accelerating drug discovery and development for biopharma
- Matching patients to relevant clinical trials
- Monitoring cancer response to treatment
- Early disease detection
What Physicians Need to Know
Physicians can leverage Caris Molecular Intelligence for comprehensive tumor profiling to obtain a complete molecular blueprint of a patient's cancer, guiding personalized treatment decisions and identifying therapies with potential benefit or lack thereof. The platform aids in matching patients to relevant clinical trials and utilizes AI tools like GPSai for accurate tumor tissue of origin prediction, particularly in complex cases. Engaging with Caris's services can help navigate data-dense genomic information to make informed, individualized treatment choices.
Caris offers robust integrations with major Electronic Health Record (EHR) systems, including enhanced partnerships with Epic (via the Orders and Results Anywhere - ORA network) and Flatiron Health (via OncoEMR). These integrations streamline clinical workflows by enabling electronic test ordering, real-time status updates, and direct receipt of comprehensive molecular profiling results within the physician's existing patient care platform, ensuring seamless access to structured genomic data.
Details
| Category | Drug Discovery & Research, Oncology AI |
| Pricing | Not publicly disclosed |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Caris' MI Cancer Seek™ has received U.S. Food and Drug Administration (FDA) approval as a companion diagnostic (CDx) test. It is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors, intended to identify patients who may benefit from targeted therapies and for tumor mutational profiling. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pathology |
What the Web Says
Caris Molecular Intelligence offers comprehensive tumor profiling services that analyze DNA, RNA, and proteins to provide a molecular blueprint of a patient's cancer. This information assists physicians in making personalized treatment decisions, potentially leading to improved outcomes and increased overall survival for patients with advanced, refractory, or rare solid tumors. The company also focuses on advancing precision medicine through Next Generation Profiling, combining its services with proprietary AI analytics. While patient testimonials highlight the life-saving potential and personalized treatment benefits, employee reviews often point to significant internal management and culture issues.
Overall: MixedStrengths
- Provides comprehensive molecular profiling of tumors (DNA, RNA, proteins) for personalized cancer treatment.
- Associated with increased overall survival in patients with solid tumors.
- Helps physicians make more precise and personalized treatment decisions, influencing therapeutic choices in a significant percentage of cases.
- Identifies actionable biomarkers and relevant open clinical trials.
- Offers a single universal assay method to determine cancer origins, potentially making diagnosis faster, easier, and cheaper.
- Patient testimonials express strong positive experiences, crediting Caris with saving lives and providing hope.
Limitations
- Employee reviews frequently cite poor management, toxic culture, and favoritism.
- Concerns about job security and advancement opportunities for employees.
- Work-life balance is often rated poorly by employees.
- Billing and insurance processes can be complex and problematic for patients.
- Some Reddit discussions about Caris as an employer indicate a high turnover rate and a challenging work environment.
- The cost-effectiveness of the multiplatform testing, while potentially beneficial due to improved survival, still requires further randomized studies for broader access and reimbursement discussions.
Based on reviews from: Indeed.com, Zippia, Caris Life Sciences (Patient Stories), PR Newswire, PMC (PubMed Central), ResultMed, HTA Database - inahta, Reddit, Mayo Clinic Connect, TIKR.com
Last updated: 2026-07-24
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Caris Molecular Intelligence
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Caris Molecular Intelligence.
Tissue-Based Comprehensive Molecular Profiling
Frequently Asked Questions
Investors who backed Caris Molecular Intelligence
Funded through the company that built this tool.
